Mar 21, 2018
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
Immutep Commences Patient Dosing In Additional TACTI-mel Cohort
Mar 11, 2018
Immutep Raises A$6.85M Through Institutional Placement
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
Mar 05, 2018
Immutep Announces United States Patent Grant for IMP701 Antibody
Mar 04, 2018
Immutep receives A$686,704 R&D Tax Incentive
Feb 08, 2018
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
Jan 31, 2018
Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma
Dec 11, 2017
Operational Update
Nov 28, 2017
Prima BioMed Becomes Immutep
Nov 20, 2017
FAQ – Change of company name from ‘Prima BioMed Limited’ to ‘Immutep Limited’
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
